- Home
- BMO vs BDX Comparison
BMO vs BDX Comparison
Compare BMO & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | BDX |
|---|---|---|
| Founded | 1817 | 1897 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2B | 43.0B |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BMO | BDX |
|---|---|---|
| Price | $175.16 | $185.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $163.00 | ★ $186.00 |
| AVG Volume (30 Days) | 681.8K | ★ 1.6M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.25% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $4.27 | $3.02 |
| P/E Ratio | ★ $17.46 | $117.94 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $119.84 | $140.11 |
| 52 Week High | $187.22 | $213.08 |
Technical Indicators
Market Signals| Indicator | BMO | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 64.39 |
| Support Level | $173.99 | $141.69 |
| Resistance Level | $185.72 | $193.07 |
| Average True Range (ATR) | 3.73 | 3.89 |
| MACD | -0.44 | -1.08 |
| Stochastic Oscillator | 47.33 | 55.06 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.